Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Codeine vs PERIOGARD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.
Chlorhexidine gluconate is a cationic bisbiguanide that disrupts microbial cell membrane integrity, leading to leakage of intracellular contents and cell death. It exhibits broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses.
FDA-approved for mild to moderate pain where an opioid is appropriate,FDA-approved for cough suppression,Off-label: acute pain, chronic pain (limited use)
Treatment of gingivitis characterized by redness, swelling, and bleeding, including bleeding on probing,Off-label: Oral mucositis, peri-implantitis, dental caries prevention, reduction of oral bacterial load in immunocompromised patients
Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.
15 m L chlorhexidine gluconate 0.12% oral rinse twice daily for 30 seconds and expectorate.
The terminal elimination half-life of codeine is approximately 2.5 to 3.5 hours in adults with normal renal function. In patients with renal impairment, the half-life may be prolonged to up to 8 hours, necessitating dose adjustment.
6-7 hours (prolonged in renal impairment; no dosage adjustment for topical oral use).
Codeine is metabolized by CYP2D6 to morphine (active), via CYP3A4 to norcodeine (inactive), and via glucuronidation. Morphine is further conjugated via UGT2B7.
Chlorhexidine is not significantly absorbed systemically following oral topical application; minimal metabolism occurs in the liver, with primary excretion via feces.
Codeine is eliminated primarily via renal excretion (about 90% as inactive metabolites, mainly codeine-6-glucuronide and norcodeine, with less than 10% as free codeine). Biliary/fecal excretion accounts for approximately 10% of the dose.
Primarily renal (70-80% unchanged via glomerular filtration); minor biliary/fecal (20-30%).
Approximately 25% bound to plasma proteins, primarily albumin.
Very low (10-18%), primarily to serum proteins (albumin).
Approximately 3-6 L/kg, indicating extensive distribution into tissues, including brain and breast milk.
0.2-0.3 L/kg (minimal systemic distribution, consistent with poor absorption from oral topical use).
Oral bioavailability is about 60-90% (first-pass metabolism reduces systemic exposure; extensive metabolizers may have higher morphine levels). Rectal bioavailability is similar to oral. Intramuscular and subcutaneous routes have nearly 100% bioavailability.
Topical oral (mouthwash): <1% (minimal systemic absorption).
Cr Cl 10-50 m L/min: Administer 75% of normal dose. Cr Cl <10 m L/min: Administer 50% of normal dose. Not recommended in severe renal impairment due to risk of CNS toxicity.
No dose adjustment required; negligible systemic absorption.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% or use alternative. Child-Pugh Class C: Contraindicated. Avoid in severe hepatic impairment due to decreased metabolism and risk of accumulation.
No dose adjustment required; negligible hepatic metabolism.
Oral, IM, or SC: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum 60 mg/dose. Weight-based dosing for children >1 year. Not recommended in children under 12 years for postoperative tonsillectomy/adenoidectomy. Contraindicated in children <12 years for pain, and <18 for cough due to risk of respiratory depression.
Not recommended for children under 18 years due to safety and efficacy data lacking.
Start at low end of dosing range (e.g., 30 mg every 4-6 hours) due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment. Monitor renal function and avoid in patients with Cr Cl <30 m L/min. Consider non-opioid alternatives first.
No specific dose adjustment; use with caution if dysphagia or aspiration risk present.
WARNING: CODEFINE HAS RISKS OF ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. LIFE-THREATENING RESPIRATORY DEPRESSION MAY OCCUR, ESPECIALLY IN CHILDREN, AND RISK IS INCREASED WITH CYP2D6 ULTRA-RAPID METABOLIZERS. PROLONGED USE DURING PREGNANCY CAN RESULT IN NEONATAL OPIOID WITHDRAWAL SYNDROME.
No FDA black box warning.
CYP2D6 ultra-rapid metabolizers: risk of morphine toxicity, fatal respiratory depression,Life-threatening respiratory depression in children <12 years; contraindicated in <18 years for tonsillectomy/adenoidectomy,Risk of opioid-induced respiratory depression, especially in elderly, debilitated, or patients with respiratory conditions,Addiction, abuse, and misuse potential,Neonatal opioid withdrawal syndrome if used during pregnancy,Concomitant use with CNS depressants increases risk of hypotension, respiratory depression, and coma,Serotonin syndrome with serotonergic drugs,Severe hypotension, including orthostatic hypotension,Adrenal insufficiency with prolonged use,Increased risk of seizures in patients with seizure disorders,May impair ability to drive or operate machinery
Avoid contact with eyes, ears, and mucous membranes; may cause staining of teeth, tongue, and dental restorations; hypoesthesia of tongue may occur; anaphylaxis and serious allergic reactions reported; use with caution in patients with known hypersensitivity; not for use in children under 6 years.
Hypersensitivity to codeine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Paralytic ileus (known or suspected),Postoperative management in children <18 years after tonsillectomy/adenoidectomy,Children <12 years,Use with MAOIs or within 14 days of stopping MAOIs
Hypersensitivity to chlorhexidine gluconate or any component of the formulation
Avoid alcohol completely; increase risk of CNS depression and hepatotoxicity. Grapefruit juice may inhibit CYP3A4, affecting codeine metabolism; limited data but caution advised. High-fiber foods may help counteract constipation. No significant food restrictions aside from alcohol.
Avoid food, beverages, and other oral care products (e.g., toothpaste) for 30 minutes after rinsing to prevent inactivation. Specifically, sodium lauryl sulfate in toothpaste can reduce efficacy. There are no known direct food interactions with chlorhexidine rinse beyond timing of use.
FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal after birth. Avoid in labor due to neonatal respiratory depression.
Periogard (chlorhexidine gluconate oral rinse) has not been studied in pregnant women. Animal reproduction studies have not been conducted. Based on limited systemic absorption, risk to fetus is considered low. However, due to insufficient data, use in pregnancy is generally avoided, especially during first trimester, unless clearly needed.
Codeine is excreted into breast milk; M/P ratio approximately 2.0. Use with caution; risk of infant opioid toxicity, especially in CYP2D6 ultra-rapid metabolizers. Not recommended for breastfeeding mothers.
No data on excretion in human milk. Because chlorhexidine is poorly absorbed after oral administration, levels in breast milk are expected to be negligible. M/P ratio unknown. Use with caution in nursing mothers, but considered compatible with breastfeeding due to minimal systemic absorption.
Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; however, avoid due to risks. No standard adjustment; use lowest effective dose for shortest duration if necessary.
No pharmacokinetic studies available. Due to negligible systemic absorption, dose adjustment is not anticipated in pregnancy. However, use only if clearly needed, as data are lacking.
Codeine is a prodrug requiring CYP2D6 metabolism to morphine; poor metabolizers have reduced efficacy, while ultra-rapid metabolizers risk toxicity. Avoid in children <12 years for post-tonsillectomy/adenoidectomy due to fatal respiratory depression. Monitor for constipation; prescribe laxative with chronic use. Contraindicated with MAOIs and within 14 days of their discontinuation. Not effective for acute pain needing immediate relief due to variable conversion.
PERIOGARD (chlorhexidine gluconate 0.12%) oral rinse is used as an adjunct to periodontal treatment. It is most effective when used 30 minutes after brushing to avoid inactivation by sodium lauryl sulfate in toothpaste. Patients should be advised to avoid eating or drinking for 30 minutes after rinsing. The most common side effect is extrinsic tooth staining, which can often be removed by dental prophylaxis. Rinsing with 15 m L for 30 seconds twice daily is typical. Do not swallow; if accidental ingestion occurs, consider potential for alcohol toxicity (contains 11.6% alcohol).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not combine with alcohol, sedatives, or other CNS depressants (e.g., benzodiazepines) due to risk of severe drowsiness, respiratory depression, or coma.,Common side effects include constipation, nausea, dizziness, and drowsiness. Drink plenty of fluids and consider stool softeners for constipation.,Avoid driving or operating machinery until you know how codeine affects you, as it may impair judgment and coordination.,Inform your doctor if you have a history of asthma, breathing problems, liver or kidney disease, or if you are pregnant or breastfeeding.,Do not share this medication with others, especially children; accidental use can be fatal. Store securely out of reach of children.,If you miss a dose, take it as soon as you remember. If near the next dose, skip the missed one; do not double dose.,Do not stop abruptly after prolonged use; taper under medical supervision to avoid withdrawal symptoms (anxiety, sweating, insomnia, diarrhea).
Use exactly as directed: 15 m L (1 tablespoon) for 30 seconds twice daily after brushing.,Do not swallow the rinse; spit it out after use.,Avoid eating, drinking, or rinsing with other mouthwashes for at least 30 minutes after use.,Temporary taste alteration or numbness of the tongue may occur initially.,May cause brown staining of teeth, tongue, or dental restorations; regular dental cleaning can remove stains.,Do not dilute the solution; use full strength.,If you have mouth ulcerations or oral surgery, consult your dentist before use.,Keep out of reach of children.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Codeine vs PERIOGARD, answered by our medical review team.
Codeine is a Opioid Agonist that works by Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.. PERIOGARD is a Antiseptic mouthwash that works by Chlorhexidine gluconate is a cationic bisbiguanide that disrupts microbial cell membrane integrity, leading to leakage of intracellular contents and cell death. It exhibits broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Codeine and PERIOGARD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Codeine is: Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.. The standard adult dose of PERIOGARD is: 15 m L chlorhexidine gluconate 0.12% oral rinse twice daily for 30 seconds and expectorate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Codeine and PERIOGARD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Codeine is classified as Category D/X. FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal . PERIOGARD is classified as Category C. Periogard (chlorhexidine gluconate oral rinse) has not been studied in pregnant women. Animal reproduction studies have not been conducted. Based on limited systemic absorption, ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.